DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for spinal cord cancer — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSpinal cord cancer maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for spinal cord cancer is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
adrenoceptor alpha 2C (ADRA2C) — ADRA2C is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 8~{a}~{r},12~{a}~{s},13~{a}~{r}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6KUW · 2.8 Å · ligand (8~{a}~{R},12~{a}~{S},13~{a}~{R})-12-ethylsulfonyl-3-methoxy-5,6,8,8~{a},9,10,11,12~{a},13,13~{a}-decahydroisoquinolino[2,1-g][1,6]naphthyridine (E33). Experimental structure, not a prediction.
What the evidence adds up to
Intramedullary spinal cord tumours are rare and the majority of patients can initially be treated with attempted surgical resection. For those who cannot have a gross-total resection, or who have a subtotal resection, the remaining options are radiotherapy and chemotherapy, both of which carry significant adverse side effects and still leave patients with a poor prognosis. A 2015 review states that novel treatment options must be developed to supplement subtotal resection, with research underway into directed, localised drug delivery and nanomedicine techniques. A 1996 study of seven unrelated patients with sporadic intramedullary spinal cord ependymomas found detectable mutations in the NF2 gene transcript in five of the seven tumours; all mutations occurred in a region homologous to cytoskeletal proteins and resulted in significant truncation of the predicted protein product, likely rendering it inactive.
Spinal metastases are common in patients with cancer, and as cancer treatments improve and patients live longer, the number presenting with metastatic spine disease will increase. A 2019 review notes that since a 2005 randomised controlled trial by Patchell et al. showed increased survival with decompressive surgical treatment of spinal metastases, there has been growing literature on surgical management and complications. Surgery is often one component of a multimodal approach with chemotherapy and radiation, making it difficult to parse the benefits of each individual treatment in outcome studies. Metastatic spinal cord compression is a feature of advanced cancer, and a 2014 article describes a multidisciplinary project aimed at improving care for newly diagnosed patients admitted for radiotherapy, covering mobilisation, medications including steroids and thromboprophylaxis, bowel management, patient priorities, discharge planning, and early detection.
A 2013 review found that patients with spinal cord tumours who participate in rehabilitation programmes show general improvement in function, mood, quality of life, and survival, despite increased medical co-morbidity and neurological deficits. The same review notes that access to treatment should be increased given improved survival and functional deficits, and that adjustments to care plans must incorporate medical complications from cancer and its treatment, perceived quality of life, and prognosis. A 2025 update on molecular targets in neuro-oncology states that signalling pathways regulating cellular processes such as growth, division, and survival are frequently dysregulated in cancer, and that targeting these pathways has enabled the development of personalised therapies that improve efficacy while minimising side effects, driving innovation in drug discovery.
What is still missing are large, prospective trials that can isolate the benefit of any single treatment modality in multimodal settings, validated patient stratification tools to match specific molecular targets to individual tumours, and dedicated funding for rehabilitation research that addresses the neurological sequelae of spinal cord tumours rather than focusing solely on acute oncological management.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurosurgical FOCUS · 2015 · 187 citations · open access
Intramedullary spinal cord tumors: a review of current and future treatment strategies
AbstractIntramedullary spinal cord tumors have low incidence rates but are associated with difficult treatment options. The majority of patients with these tumors can be initially treated with an attempted resection. Unfortunately, those patients who cannot undergo gross-total resection or have subtotal resection are left with few treatment options, such as radiotherapy and chemotherapy. These adjuvant treatments, however, are associated with the potential for significant adverse side effects and still leave patients with a poor prognosis. To successfully manage these patients and improve both their quality of life and prognosis, novel treatment options must be developed to supplement subtotal resection. New research is underway investigating alternative therapeutic approaches for these patients, including directed, localized drug delivery and nanomedicine techniques. These and other future investigations will hopefully lead to promising new therapies for these devastating diseases.
Frequent Type 2 Neurofibromatosis Gene Transcript Mutations in Sporadic Intramedullary Spinal Cord Ependymomas
AbstractOBJECTIVE: To further investigate the role of Type 2 neurofibromatosis (NF2) gene transcript mutations in the sporadically occurring counterparts of NF2-associated tumors. METHODS: Reverse transcription-polymerase chain reaction followed by agarose gel electrophoresis, single strand conformation polymorphism analysis, and automated deoxyribonucleic acid sequence analysis were used to screen for mutations in the NF2 gene transcript in seven unrelated patients with sporadic intramedullary spinal cord ependymomas. RESULTS: Five of seven intramedullary spinal cord ependymomas harbored detectable mutations. All of these mutations occurred in the region of the transcript that is homologous to known cytoskeletal proteins and resulted in significant truncation of the predicted protein product. CONCLUSION: Mutations of the NF2 transcript occur in the majority of sporadic intramedullary spinal cord ependymomas. These mutations are frequent in a region of the transcript that is homologous to a family of cytoskeletal proteins, and they probably render the protein product inactive. These results add to the body of knowledge concerning the role of the NF2 gene transcript in tumorigenesis.
Annals of Translational Medicine · 2019 · 68 citations · open access
Treatment, complications, and outcomes of metastatic disease of the spine: from Patchell to PROMIS
AbstractSpinal metastases are common in patients with cancer. As cancer treatments improve and these patients live longer, the number who present with metastatic spine disease will increase. Treatment strategies for these patients continues to evolve. In particular, since the prospective randomized controlled study in 2005 by Patchell et al . showed increased survival with decompressive surgical treatment of spinal metastases, there is a growing body of literature focusing on surgical management and complications of surgery for this disease. Surgery is often one component of a multimodal treatment approach with chemotherapy and radiation, which makes it difficult to parse the benefits of each individual treatment in outcome studies. Additionally, there has been more recent emphasis placed on patient-reported outcomes (PRO) after treatment for metastatic spine disease. In this review, we summarize treatments of metastatic spinal disease, possible perioperative complications, and validated tools used to assess outcomes for these patients.
Journal of Spinal Cord Medicine · 2013 · 64 citations · open access
Rehabilitation and treatment of spinal cord tumors
AbstractCONTEXT: Due to advances in acute oncological treatment, patients with spinal cord tumors exhibit improved survival. However, these patients have not received the full benefits of rehabilitation services to address their neurological deficits and rehabilitation goals. OBJECTIVE: To evaluate the epidemiology and pathophysiology of spinal cord tumors, address methods of acute oncological management, review treatment for neurological sequelae, and understand the implications as they relate to rehabilitation. METHODS: An extensive literature review was performed regarding the epidemiology, pathophysiology, acute oncological management, neurological sequelae, and rehabilitation for patients with spinal cord tumors. Databases used included pubmed.gov and OVID, as well as individual journal and textbook articles. RESULTS: Access to treatment should be increased given improved survival and functional deficits for patients with spinal cord tumors. Individuals can benefit from inpatient rehabilitation programs, in spite of increased medical co-morbidity and neurological deficits. Specific areas of improvement include functionality, mood, quality of life, and survival. Adjustments to treatment plans must incorporate medical complications from cancer and its treatment, perceived quality of life, and prognosis. CONCLUSIONS: Patients with spinal cord tumors who participate in rehabilitation programs show general improvement in function, mood, quality of life, and survival. Adaptations to care plans should be made to accommodate medical co-morbidities from cancer and its treatment, patient perceptions, and prognosis.
Improving care of patients with metastatic spinal cord compression
AbstractMetastatic spinal cord compression is a feature of advanced cancer and the incidence is likely to increase alongside improved survival rates. Patients with spinal cord compression have complex physical, psychological and social care needs. This article describes a multidisciplinary project aimed at improving the care provided to newly diagnosed patients who were admitted to a regional cancer centre for radiotherapy. The project used a range of approaches to measure care, develop and implement interventions, and evaluate outcomes. Aspects of care reviewed in the project included mobilisation, medications including steroids and thrombo-prophylaxis, bowel management, patient priorities and concerns, discharge planning and early detection.
Journal of Environmental Pathology Toxicology and Oncology · 2025 · 0 citations
Deciphering Novel Molecular Targets in Neuro-Oncology: An Update
AbstractNeuro-oncology is the study of brain and spinal cord neoplasms. Molecular targets and signaling pathways are pivotal in advancing modern healthcare, particularly in personalized medicine. Signaling pathways, which regulate cellular processes such as growth, division, and survival, are frequently dysregulated in cancer. Targeting these pathways has enabled the development of personalized therapies that improve efficacy while minimizing side effects. This approach has led to significant improvements in patient outcomes, reduced treatment toxicity, and a shift toward precision medicine, driving innovation in drug discovery. The integration of molecular targets and signaling pathways into clinical practice highlights their importance for enhancing patient care.
Zenodo (CERN European Organization for Nuclear Research) · 2022 · 0 citations · open access
TREATMENT , DIAGNOSIS AND REMOVAL OF SPINAL TUMORS BY MICROSURGERY
Abstract<em>Dear Reader, This article provides information about spinal cord cancer, a dangerous disease that has its place in world medicine today. Causes of spinal tumors, Tumors and their description, symptoms of lumbosacral spinal tumors, as well as information on the diagnosis and treatment of this disease. You can get much-needed information about traditional and surgical methods used in treatment. This article also provides information on tinctures used in the treat ment of cancer. You can learn about the stages of its preparation.</em>
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
